研究领域

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer

发布时间:2017/5/23 浏览量:322

Hang Zhang, Yuxi Wang, Yangping Wu, Xiaohua Jiang, Yiran Tao, Yuqin Yao, Yujia Peng, Xiangzheng Chen, Yuyin Fu, Lin Yu, Ruixue Wang, Qinhuai Lai, Weirong Lai, Wenting Li, Yuhuan Kang, Shuli Yi, Ying Lu, Lantu Gou, Min Wu and Jinliang Yang

Signal Transduction and Targeted Therapy 2, Article number: 17015 (2017)  doi:10.1038/sigtrans.2017.15

Abstract:

Antibody–drug conjugates (ADCs) take the advantage of monoclonal antibodies to selectively deliver highly potent cytotoxic drugs to tumor cells, which have become a powerful measure for cancer treatment in recent years. To develop a more effective therapy for human epidermal growth factor receptor 2 (HER2)-positive cancer, we explored a novel ADCs composed of anti-HER2 scFv–HSA fusion antibodies conjugates with a potent cytotoxic drug DM1. The resulting ADCs, T-SA1–DM1 and T-SA2–DM1 (drug-to-antibody ratio in the range of 3.2–3.5) displayed efficient inhibition in the growth of HER2-positive tumor cell lines and the half-maximal inhibitory concentration on SKBR-3 and SKOV3 cells were both at the nanomolar levels in vitro. In HER2-positive human ovarian cancer xenograft models, T-SA1–DM1 and T-SA2–DM1 also showed remarkable antitumor activity. Importantly, three out of six mice exhibited complete remission without regrowth in the high-dose group of T-SA1–DM1. On the basis of the analysis of luminescence imaging, anti-HER2 scFv–HSA fusion antibodies, especially T-SA1, showed strong and rapid tumor tissue penetrability and distribution compared with trastuzumab. Collectively, the novel type of ADCs is effective and selective targeting to HER2-positive cancer, and may be a promising antitumor drug candidate for further studies.

▲ Figure: Distribution of trastuzumab, T-SA1 and T-SA2 in vivo was displayed by bioluminescence imaging system. Both T-SA1 and T-SA2 could target tumor tissues specifically within 2 h post injection and the maximum fluorescence intensity on the area of tumor was observed at 12 h post injection. The tumor tissue areas were shown with the red arrows. The liver areas were shown with the blue arrows.

全文链接:https://www.nature.com/articles/sigtrans201715

厦门大学分子影像暨转化医学研究中心 福建省分子影像诊疗工程技术研究中心 厦门市分子影像工程技术研究中心 版权所有
地址:福建省厦门市翔安区翔安南路厦门大学曾辉楼,邮编:361102
电话:0592-2880646,邮箱:xiamen-cmitm@xmu.edu.cn